Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Nektar Therapeutics

NASDAQ: NKTR · Life Sciences · 5 alerts · CIK 906709

Share price
$36.44Close, Nov 16
Market cap
$1.25B
Shares outstanding
34.21MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Nektar Therapeutics filings on SEC EDGAR ↗

6:07 AM ET 8-K
Investor Meeting

Nektar Therapeutics Investor Meeting

Nektar Therapeutics reaffirmed its financial guidance, stating that its current cash and marketable securities balance of $952.9 million is expected to fund operations into the third quarter of 2028. This runway is intended to support the company through the initial Phase 3 data readouts for its ZENITH AD trials in atopic dermatitis, expected in the summer of 2028.

6:02 AM ET 10-Q
Financial Results

Nektar Therapeutics Q3 2026 Results: Net Loss of $55.7M, Loss Widens

Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on developing rezpegaldesleukin (NKTR-358) for autoimmune diseases. The company reported a transition to a non-accelerated filer status and continues to incur substantial net losses while relying on collaboration agreements and capital markets for funding.

Key figure
Net loss $55.7M
4:26 PM ET 8-K
Financial Results

Nektar Therapeutics Financial Results

Nektar Therapeutics reported third quarter 2026 financial results, highlighting a cash position of $952.9 million and the initiation of Phase 3 registrational trials for rezpegaldesleukin in atopic dermatitis. The company reported a net loss of $55.7 million on revenue of $9.4 million, with R&D expenses increasing to support its late-stage clinical programs.

Term
Q3 2026

“This was a pivotal quarter for Nektar as we moved rezpegaldesleukin quickly into Phase 3 development. We have now initiated all three global ZENITH AD registrational trials in atopic dermatitis and our global ZENITH AA registrational trial in alopecia areata is on track to begin in December, earlier than previously planned.”

Howard Robin, President and Chief Executive Officer of Nektar
7:59 AM ET 8-K
Clinical Trial Data

Nektar Therapeutics Clinical Trial Data

Nektar Therapeutics announced long-term Phase 2b data for rezpegaldesleukin in patients with alopecia areata (REZOLVE-AA) and atopic dermatitis (REZOLVE-AD) at the EADV Congress 2026. The data demonstrated sustained hair regrowth and deepening of response even six months after treatment cessation, suggesting a differentiated regulatory T cell (Treg) mechanism compared to existing systemic therapies.

Earnings call
Oct 1, 2026, 3:00 PM ET
7:00 AM ET 8-K
Court & Legal Update

Nektar Therapeutics Court & Legal Update

A jury in the U.S. District Court for the Northern District of California awarded Nektar Therapeutics $90 million in damages plus interest in its lawsuit against Eli Lilly. The jury found that Lilly breached the implied covenant of good faith and fair dealing regarding the license agreement for rezpegaldesleukin. The verdict remains subject to post-trial proceedings and potential appeals.

Counterparty
Eli Lilly and Company

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.